190 related articles for article (PubMed ID: 12885235)
1. Fibrillar aggregates of the tumor suppressor p53 core domain.
Ishimaru D; Andrade LR; Teixeira LS; Quesado PA; Maiolino LM; Lopez PM; Cordeiro Y; Costa LT; Heckl WM; Weissmüller G; Foguel D; Silva JL
Biochemistry; 2003 Aug; 42(30):9022-7. PubMed ID: 12885235
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.
Ano Bom AP; Rangel LP; Costa DC; de Oliveira GA; Sanches D; Braga CA; Gava LM; Ramos CH; Cepeda AO; Stumbo AC; De Moura Gallo CV; Cordeiro Y; Silva JL
J Biol Chem; 2012 Aug; 287(33):28152-62. PubMed ID: 22715097
[TBL] [Abstract][Full Text] [Related]
3. The (1-63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies.
Rigacci S; Bucciantini M; Relini A; Pesce A; Gliozzi A; Berti A; Stefani M
Biophys J; 2008 May; 94(9):3635-46. PubMed ID: 18199664
[TBL] [Abstract][Full Text] [Related]
4. Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain.
Kovachev PS; Banerjee D; Rangel LP; Eriksson J; Pedrote MM; Martins-Dinis MMDC; Edwards K; Cordeiro Y; Silva JL; Sanyal S
J Biol Chem; 2017 Jun; 292(22):9345-9357. PubMed ID: 28420731
[TBL] [Abstract][Full Text] [Related]
5. Conversion of wild-type p53 core domain into a conformation that mimics a hot-spot mutant.
Ishimaru D; Maia LF; Maiolino LM; Quesado PA; Lopez PC; Almeida FC; Valente AP; Silva JL
J Mol Biol; 2003 Oct; 333(2):443-51. PubMed ID: 14529628
[TBL] [Abstract][Full Text] [Related]
6. Aggregation-primed molten globule conformers of the p53 core domain provide potential tools for studying p53C aggregation in cancer.
Pedrote MM; de Oliveira GAP; Felix AL; Mota MF; Marques MA; Soares IN; Iqbal A; Norberto DR; Gomes AMO; Gratton E; Cino EA; Silva JL
J Biol Chem; 2018 Jul; 293(29):11374-11387. PubMed ID: 29853637
[TBL] [Abstract][Full Text] [Related]
7. Reversible amyloid formation by the p53 tetramerization domain and a cancer-associated mutant.
Lee AS; Galea C; DiGiammarino EL; Jun B; Murti G; Ribeiro RC; Zambetti G; Schultz CP; Kriwacki RW
J Mol Biol; 2003 Mar; 327(3):699-709. PubMed ID: 12634062
[TBL] [Abstract][Full Text] [Related]
8. Reversible aggregation plays a crucial role on the folding landscape of p53 core domain.
Ishimaru D; Lima LM; Maia LF; Lopez PM; Ano Bom AP; Valente AP; Silva JL
Biophys J; 2004 Oct; 87(4):2691-700. PubMed ID: 15298872
[TBL] [Abstract][Full Text] [Related]
9. The p53 core domain is a molten globule at low pH: functional implications of a partially unfolded structure.
Bom AP; Freitas MS; Moreira FS; Ferraz D; Sanches D; Gomes AM; Valente AP; Cordeiro Y; Silva JL
J Biol Chem; 2010 Jan; 285(4):2857-66. PubMed ID: 19933157
[TBL] [Abstract][Full Text] [Related]
10. Biophysical characterization of p53 core domain aggregates.
Lima I; Navalkar A; Maji SK; Silva JL; de Oliveira GAP; Cino EA
Biochem J; 2020 Jan; 477(1):111-120. PubMed ID: 31841126
[TBL] [Abstract][Full Text] [Related]
11. Relevance of Amorphous and Amyloid-Like Aggregates of the p53 Core Domain to Loss of its DNA-Binding Activity.
Hibino E; Tenno T; Hiroaki H
Front Mol Biosci; 2022; 9():869851. PubMed ID: 35558561
[TBL] [Abstract][Full Text] [Related]
12. Pressure-temperature folding landscape in proteins involved in neurodegenerative diseases and cancer.
Cordeiro Y; Foguel D; Silva JL
Biophys Chem; 2013 Dec; 183():9-18. PubMed ID: 23849959
[TBL] [Abstract][Full Text] [Related]
13. Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation.
Ishimaru D; Ano Bom AP; Lima LM; Quesado PA; Oyama MF; de Moura Gallo CV; Cordeiro Y; Silva JL
Biochemistry; 2009 Jul; 48(26):6126-35. PubMed ID: 19505151
[TBL] [Abstract][Full Text] [Related]
14. Elucidating the Mechanisms of R248Q Mutation-Enhanced p53 Aggregation and Its Inhibition by Resveratrol.
Liu Q; Li L; Yu Y; Wei G
J Phys Chem B; 2023 Sep; 127(36):7708-7720. PubMed ID: 37665658
[TBL] [Abstract][Full Text] [Related]
15. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva JL; Rangel LP; Costa DC; Cordeiro Y; De Moura Gallo CV
Biosci Rep; 2013 Jul; 33(4):. PubMed ID: 24003888
[TBL] [Abstract][Full Text] [Related]
16. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity.
Lasagna-Reeves CA; Clos AL; Castillo-Carranza D; Sengupta U; Guerrero-Muñoz M; Kelly B; Wagner R; Kayed R
Biochem Biophys Res Commun; 2013 Jan; 430(3):963-8. PubMed ID: 23261448
[TBL] [Abstract][Full Text] [Related]
17. Nucleophosmin contains amyloidogenic regions that are able to form toxic aggregates under physiological conditions.
Di Natale C; Scognamiglio PL; Cascella R; Cecchi C; Russo A; Leone M; Penco A; Relini A; Federici L; Di Matteo A; Chiti F; Vitagliano L; Marasco D
FASEB J; 2015 Sep; 29(9):3689-701. PubMed ID: 25977257
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
19. Amyloidogenicity of p53: a hidden link between protein misfolding and cancer.
Gong H; Yang X; Zhao Y; Petersen RB; Liu X; Liu Y; Huang K
Curr Protein Pept Sci; 2015; 16(2):135-46. PubMed ID: 25692950
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of insulin within its self-assembly and amyloidogenic pathways.
Grudzielanek S; Velkova A; Shukla A; Smirnovas V; Tatarek-Nossol M; Rehage H; Kapurniotu A; Winter R
J Mol Biol; 2007 Jul; 370(2):372-84. PubMed ID: 17521669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
